Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

GenSight investment profits from gene therapy buzz

Authored by James Sheppard French gene therapy company GenSight Biologics recently announced they had raised 32m euros in series A funding. The funding was led by the corporate venture capital fund, Novartis Venture Fund. Other notable investors included Abingworth LLP … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

AstraZeneca Binds to biologics for new strategy Horizon

Authored by James Sheppard On April 3rd AstraZeneca announced that MedImmune, its global biologics R&D unit, had completed the purchase of US biotech AlphaCore Pharma, for an undisclosed sum. AlphaCore are developing ACP-501 for the treatment of LCAT Deficiency Syndrome … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Santhera seeks US partner for DMD program

Authored by Karl Simpson Last week also bought news from another company with a product in the DMD area, Santhera Pharmaceuticals. The company released news that the Phase III DELOS (DuchEnne Muscular Dystrophy Long-term IdebenOne Study) study of orally administered … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , | Leave a comment

David Motts’ NEA weighs in on rare diseases

Authored by Karl Simpson David Mott is a man who is used to making a difference to the life sciences landscape. The ex-CEO of MedImmune was instrumental in selling the company to AstraZeneca for $15.6bn. Since 2008, he has been … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

Shire starts year with flurry of deals

Authored by James Sheppard One of the people featured in the 13 life science people to watch in 2013 was Shire CEO Flemming Ornskov, who will officially take the helm as CEO-proper in May. It was clear that Shire needed … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , | Leave a comment

It’s as simple as ADC for Mersana Therapeutics

Authored by Karl Simpson Earlier this month, as I gathered with prominent pharmaceutical leaders to discuss the challenges and opportunities of orphan drugs at the World Orphan Drug Congress in Washington, up the road was the Annual Meeting of the … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap